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Case presentation
DR. GIOVANNI BANFI (Assistant in Nephrology, Ospedale Maggiore
Policlinico, Milano, Italy): A 52-year-old man was admitted to the
Nephrology Division of the Ospedale Maggiore of Milan for investiga-
tion of the nephrotic syndrome. He had been well until one year before,
when he began to notice peripheral edema. After some weeks he
consulted a physician, who obtained the following laboratory data:
plasma creatinine, 1.0 mg/dl; BUN, 10 mg/dl; total serum protein, 5.4 g/
dl; urinary protein, 5 g/24 hours; and microhematuria. A renal biopsy
was recommended, but the patient refused. Hydrochlorothiazide, 50 mg
daily, was prescribed. The edema worsened over the succeeding
months and became resistant to progressively higher doses of diuretic
agents.
At admission, the temperature was 36,2°C; pulse, 90; respirations, 18/
mm; and blood pressure, 160/100 mm Hg. The patient appeared to be
well. No lymphadenopathy was present. The head and neck were
normal. Rales were heard over the lower third of both lung fields. The
cardiac examination and peripheral pulses were normal. Abdominal
examination revealed evidence of ascites. There was marked edema
over the sacral area as well as below the knees.
Plasma creatinine was 1.3 mg/dl; BUN, 25 mg/dl; hematocrit, 44%;
white blood cell count, 8,000/mm3 with a normal differential; platelet
count, 290,000/mm3; plasma sodium, 132 mEq/liter; potassium, 3.2
mEq/liter; and chloride, 98 mEq/liter. The erythrocyte sedimentation
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rate was 30 mmlhr. The total serum protein was 4.8 gldl; albumin, 2.5 g/
dl; cholesterol, 480 mg/dl; triglycerides, 330 mg/dl; calcium, 7 mg/dl;
phosphorus 3.1 mg/dl; and uric acid, 5 mg/dl. Fasting and postprandial
blood glucose values were normal. The urine had a specific gravity of
1.018; pH, 5.6; 4+ protein; and no glucose. Red blood cells and
numerous hyaline and granular casts with lipid inclusions were found in
the sediment. Urine culture was negative. A 24-hour urine collection
contained 8 g of protein. Chest x-ray was normal. An intravenous
urogram and a sonogram revealed two kidneys of normal size with no
evidence of obstruction. The total hemolytic complement activity was
180 U (normal, 150 to 250 U); C3 was 120 and C4 35 mg/dl. Serologic
tests for rheumatoid factor, syphilis, cryoglobulins, and anti-dsDNA
antibodies were negative.
A renal biopsy was performed. On light microscopic examination, 2
obsolescent and 10 patent glomeruli were identified. The glomerular
capillary walls were diffusely and homogeneously thickened. Staining
with trichrome acid fuchsin orange G demonstrated that some capillary
loops contained many fine granular protein deposits in an epimembran-
ous position. Silver methenamine stain showed "spikes" over the outer
part of the basement membrane of some loops. Tubular structures were
well preserved. Slight focal interstitial fibrosis and mild arteriolar
sclerosis were present. Electron microscopy disclosed subepithelial
osmiophylic deposits that were separated by spikes in some areas and
which were completely incorporated into the basement membrane in
others. The epithelial cells contained many protein droplets and showed
extensive fusion of foot processes. No virus-like particles were ob-
served. Slight mesangial sclerosis also was present but no mesangial
deposits were seen. Immunofluorescence studies demonstrated diffuse,
fine granular IgG deposits distributed homogeneously along the capillary
walls in all glomeruli; C3 was deposited in a similar but fainter pattern.
A diagnosis of membranous nephropathy was made.
Discussion
DR. CLAUDIO PONTICELLI (Director, Division of Nephrology
and Dialysis, Ospedale Maggiore Policlinico, Milano, Italy):
This patient's clinical course and his biopsy are typical of
membranous glomerulonephropathy (MGN), which accounts
for approximately 30% of the cases of nephrotic syndrome (NS)
in adults [1, 2]. On renal biopsy, MGN is characterized by
uniform thickening of the glomerular capillary wall that has
occurred due to the subepithelial deposition of immune com-
plexes. Typically there is little or no associated cellular prolif-
eration even though quantitative morphometry often reveals
mesangial hypercellularity [3, 4]. From a histologic point of
view, MGN can be divided into four classes: class 1 refers to
the presence of subepithelial deposits without spikes; class 2, to
the presence of spikes and domes; class 3, to the presence of
deposits within the basement membrane; and class 4, to the
presence of membrane thickening but with resorbed deposits
[2]. In some patients MGN is associated with a recognized
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Table 1. Causes of secondary membranous
glomerulonephropathy
Association with other diseases
Systemic lupus erythematosus
Neoplasia (carcinoma,
lymphoma)
Autoimmune thyroiditis
Dermatitis herpetiformis
Sarcoidosis
Sjogren's syndrome
Sickle cell disease
Diabetes mellitus
Renal transplantation
Bullous pemphigoid
Guillain-Barré syndrome
Mixed connective tissue
disease
Renal vein thrombosis (?)
disease process orwith exposure to drugs or toxins (Table 1). In
the vast majority of patients with this condition, however, no
accompanying disease or incriminating antigen or toxin is
found, and the term idiopathic membranous nephropathy is
applied. I will devote the remainder of my discussion to the
outcome of MGN and to the therapeutic maneuvers that exist
for interfering with the natural course of the disease.
Prognosis of MGN
To assess the prognosis of a given patient with MGN, one
first must ascertain whether the disease is of the idiopathic or
secondary variety. In some instances of secondary MGN, the
identification and elimination of a specific antigen can cure the
disease [5—7]; in certain systemic and malignant diseases,
however, MGN cannot be cured because the underlying proc-
ess does not respond to treatment. Sometimes MGN is the first
manifestation of an underlying disease, preceding by months or
years any other overt evidence of the systemic process; under
these circumstances, the correct diagnosis can be greatly de-
layed. A delayed diagnosis occurs most commonly in two
conditions, systemic lupus erythematosus (SLE) and neoplasia.
The nephrotic syndrome is the initial manifestation in about
6% of patients with SLE [81 and can antedate other clinical
features, including immunologic markers, by years. Most of
these patients have MGN rather than other histopathologic
forms of lupus renal disease [9—14]. In these instances, a renal
biopsy can provide very suggestive, albeit not pathognomonic,
evidence for the presence of SLE, because a number of
histopathologic features are significantly more frequent in SLE-
related than in idiopathic MGN. Mesangial deposits revealed by
toluidine blue stain or by electron microscopy are frequent in
SLE [14—161, but occur in only 3% to 11% of patients with
idiopathic MON [4, 13, 16]. Although rare in latent SLE, small
subendothelial dense deposits can be seen and are highly
suggestive of SLE [14, 161. Tubuloreticular inclusions and
tubular basement membrane deposits are common in SLE but
rarely occur in idiopathic MGN [16]. On immunofluorescence
microscopy, IgA and Clq appear more frequently in lupus than
in idiopathic MGN [14, 16J. High-intensity Clq staining is
especially suggestive of lupus MGN [14].
Most frequent in solid tumors, MGN also can complicate
Table 2. Factors adversely influencing the prognosis of idiopathic
membranous glomerulonephropathy
Older age
Male sex
Higher levels of proteinuria
Renal functional impairment
Arterial hypertension
Advanced stage of glomerular lesions
Interstitial lesions
HLA DR3+/B8+
Hodgkin's disease [17] and non-Hodgkin's lymphoma [l8J. In
the mid 1960s, Lee et a! studied 101 adults with nephrotic
syndrome; 11 had underlying cancers, and 8 of the II had MGN
[19]. Since then, approximately 100 patients with glomerulone-
phritis associated with carcinoma have been reported [181.
About 60% have had MON and, in several instances, nephrotic
syndrome preceded the diagnosis of malignancy [17, 20, 211.
The most common tumors associated with MGN are lung
cancers, the great majority of which are bronchogenic rather
than small cell tumors. Next, in order of frequency, are tumors
of the colon and rectum, kidney, breast, and stomach. In
patients over 50 years of age who present with MGN, the
clinician should keep in mind the possible presence of a
malignancy. Renal biopsy is of little help in establishing wheth-
er MGN is associated with malignancy. The features seen on
light, electron, and immunofluoresence microscopy of idiopath-
ic and neoplasia-associated MGN are often indistinguishable
[15]. In some cases, however, mesangial deposits have been
found in MGN associated with neoplasia [14, 15].
The patient under discussion today had no identifiable sys-
temic disease, no drug exposure, and no mesangial or subendo-
thelial deposits indicative of an underlying cause. Thus, he
fulfilled the diagnostic criteria for idiopathic MGN.
The outcome of idiopathic MGN is variable. Spontaneous
remissions of proteinuria occur in some patients, and renal
function can remain stable for years in others despite persistent
proteinuria; many patients with this condition, however, die or
develop end-stage renal failure. Noel et al reported deteriora-
tion in renal function in only 19% of 116 patients followed an
average of 4.5 years [22]. By contrast, Davison and colleagues
observed a doubling of serum creatinine within a mean of 30
months in 43% of 64 patients with idiopathic MGN followed for
at least 2 years; a slower deterioration of renal function was
observed in an additional 8% [231. Franklin and coworkers
reported similar results in 32 patients with MGN, 10 of whom
(31%) developed uremia within an average of 2.7 years after
clinical onset; 4 others progressed more slowly to uremia [24].
Gluck et al reported an even greater proportion of patients, 24
of 38 (63%), who developed renal failure [25]. In the American
Collaborative Study Group, 28% of the untreated patients
showed a doubling of the serum creatinine after a mean period
of 23 months [26]. In long-term studies of untreated patients and
those treated with steroids and/or cytotoxic drugs, about one-
half of all patients died or had end-stage renal failure within 15
years after the onset of symptoms [21, 27).
Several factors seem to influence the long-term prognosis of
membranous glomerulopathy (Table 2):
Age. The outcome of MGN generally is better in children
than in adults. Olbing et al [281 and Trainin et al [29] found no
Exposure to drugs or toxic agents
Captopril
Penicillamine
Heavy metals (mercury, gold)
Organic solvents
Infections
Malaria
Leprosy
Streptococcal infection
Filariasis
Schistosomiasis
Hepatitis B, chronic active hepatitis
Syphilis (congenital and secondary)
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cases of renal insufficiency in children with MGN who were less
than 10 years of age. Habib and coworkers reported an actuarial
renal survival rate of 90% at 10 years of followup [30]. A poorer
prognosis for adults than for children with idiopathic MGN also
was reported by Pierides and colleagues [31] and Row et al [21].
Davison and colleagues reported that approximately 50% of the
untreated patients who were between 30 and 60 years of age
developed renal failure, whereas fewer of those less than 30
years old did so [23]. Of 9 patients over the age of 60, 8 showed
slow or steady deterioration of renal function. By contrast, Tu
et al did not find that age was an independent predictor of
terminal renal failure in adults with MGN [32].
Sex. Hopper et al reported that deterioration of renal function
was significantly more common in males than in females [33].
Indeed, after a mean followup of 99 months, renal function had
deteriorated in only 17% of women but had done so in 55% of
men. The women in this study fared better than did the men
whether or not they were given prednisone. This finding has
recently been confirmed by other reports [23, 32, 34].
Proteinuria. There is good agreement that patients with MGN
and nephrotic-range proteinuria are more likely to progress to
uremia than are patients with less severe proteinuria [22, 23, 32,
34]. Davison et a! reported that in 50% of untreated patients
with nephrotic syndrome at presentation of MGN, renal func-
tion deteriorated within 5 years [23]; in a review of some of the
larger series, Mallick and coworkers found that after a mean
followup of 92 months, only 7.7% of patients with MGN and
non-nephrotic proteinuria had developed end-stage renal fail-
ure, and 30.8% were in complete remission [34].
Renal function. Although some investigators have not found
the initial glomerular filtration rate to be a useful predictor of
eventual outcome [34], the consensus appears to be that im-
paired renal function at the time of diagnosis of MGN presages
terminal renal failure [23, 32].
Arterial hypertension. Only a few studies address the specific
prognostic importance of high blood pressure in MGN. Tu et al
reported that patients with systolic blood pressures between
136 and 150 mm Hg were significantly more likely (40%) to
progress to total renal failure than were those with systolic
blood pressures between 90 and 120 mm Hg (14.3%) [32].
Conversely, blood pressure did not prove to be a good index of
the outcome of patients with MGN in the American Collabora-
tive Study of the Adult Idiopathic Nephrotic Syndrome [26].
Renal vein thrombosis. This complication occurs during the
course of MGN in approximately 50% of patients. Some studies
found that neither proteinuria [35, 36] nor renal function [22, 36]
are influenced by the presence of renal venous thrombi. Others,
however, found that the acute onset of renal vein thrombosis
can jeopardize renal function in patients with MGN [37, 38].
Stage of glomerular lesions. Some investigators have found
that patients whose renal biopsy discloses stage 1 to 2 MGN are
less likely to progress to uremia than are those with stage 3 to 4
[22, 39, 40]. Others have found no correlation between staging
and eventual outcome, however [24, 31, 34].
Our own observations lead us to believe that a correlation
exists between histologic staging and the clinical course. We
studied 54 patients with idiopathic MGN who had nephrotic
syndrome at presentation and who had been followed for 4 to 20
years (mean 7.0 3.9 years) (Fig. 1). Of the 54, 28 never
received corticosteroids or cytotoxic agents, whereas 26 had
Nephrotic
syndrome
U Renal failure
or death
______
U Renal failure
or death
Fig. 2. Relationship between severity of interstitial lesion on renal
biopsy (arbitrarily scored from 0 to + + +) and clinical status at the end
of followup in 54 patients with idiopathic membranous
glomerulonephropathy.
been treated with corticosteroids, cytotoxic agents, or both. At
the end of the followup, 21 had no proteinuria, 14 were still
proteinuric but did not have nephrotic syndrome, 11 had
persistent nephrotic syndrome, and 8 had had an increase in
plasma creatinine to a level at least 50% higher than baseline. Of
the patients who became completely free of proteinuria, 19 had
had stage 1 to 2 glomerular lesions; of the 8 patients whose renal
function deteriorated, only 1 had had a stage 1 lesion at the time
of renal biopsy (Fig. 1). No significant difference existed
between patients with stage 2 and patients with stage 3, whereas
all patients with stage 4 lesions continued to have proteinuria
and 33% developed progressive renal failure.
Interstitial lesions. Ramzy et al found a good correlation
between the severity of interstitial lesions at renal biopsy and
the development of renal insufficiency [27]. By scoring the
extent and severity of the interstitial lesions according to an
arbitrary, semiquantitative scale, we found that 43% of the 54
patients who had no interstitial lesions experienced a complete
remission, 23% had a partial remission, and 10% progressed to
33.3) Completeremission
Partial
tZ2 remission
IV
10075
a) 41.5
C)
50
C.)
a) . 26
25 _
18.5
_______ 9
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Fig. 1. Relationship between histologic stage of membranous glomeru-
lonephropathy on renal biopsy and clinical status at the end offollowup
(mean 7.0 3.9 years) in 54 patients.
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F
Biopsy
stage
Followup, years
M 59
M 31
CR 0.9
S Steroids
Ch Chiorambucil
A Azathioprine
Cy Cyclophosphamide
CR Plasma creatinine
Renal biopsy
Nephrotie syndrome
Proteinuria < 2 9/24 hr
Complete remission
Increaseof p1. creatinine > 50%
— Hypertension
Fig. 3. Clinical outcome in 18 patients followed for 4 to 18 years after achieving complete remission of proteinuria.
renal failure. This pattern was quite different from that of
patients with severe interstitial lesions, none of whom had a
remission; indeed, 50% died or progressed to renal failure (Fig.
2).
Remission of proteinuria. In approximately 25% of patients
with nephrotic syndrome due to idiopathic MGN, proteinuria
eventually resolves either spontaneously or in conjunction with
therapy 1:1, 21, 22, 24, 25, 31, 33, 34, 39, 40]. Proteinuria recurs
in about one-third of patients who have been in remission 1411,
but progression to renal failure in these patients, as well as in
those whose protein excretion falls to levels less than 2.0 g/day,
is exceptional [42]. Our own experience includes 18 patients
with histologically proved MON who have been followed for at
least 4 years after complete remission of proteinuria (range, 4 to
18 years; mean, 94.5 46.1 months) (Fig. 3). Nephrotic
syndrome reappeared in 2 and non-nephrotic proteinuria re-
curred in another 2; renal function deteriorated in only one
patient who happened to be elderly and whose plasma creati-
nine doubled despite the persistent remission of proteinuria.
The HLA system. In Caucasians, an association has been
observed between MGN and some HLA antigens, notably B8,
B12, and DR3 [43—471. Recently Zuechelli and colleagues
investigated in a small group of patients the possibility that
HLA alleles might be useful for predicting the natural course of
MGN (Zucchelli P, personal communication). Patients with and
without DR3 had similar rates of spontaneous remission (4/11
versus 4/13). But when the combination DR3 with B8 was
considered, patients with DR3+/B8— were more likely to have
a remission than were those with DR3+/B8+ (3/4 versus 1/9, P
0.05).
Treatment of MGN
Uncontrolled studies. The efficacy of therapy in patients with
MGN is still debated. Some uncontrolled studies have failed to
show a benefit with corticosteroids [1, 21, 25, 31, 391, but others
have reported favorable results when high doses of prednisone
were given for protracted periods [24, 32, 48, 49]. Encouraging
results also have been reported with methylprednisolone thera-
py given in intravenous "pulses" to patients whose renal
function had already declined [50]. Suki and Chavez reported
on 19 patients treated with prednisone alone or in combination
with cyclophosphamide [511. Patients who did not respond to
steroids experienced a remission of proteinuria after the addi-
tion of cyclophosphamide; in 16 of the 19 patients proteinuria
decreased to less than 1 g/day, and normal renal function was
maintained during the mean followup of 3 years (for all 19
patients).
In a retrospective multicenter study in Italy of 186 patients
with MGN followed for 5 to 14 years, the percentage of patients
in complete remission at the end of followup was significantly
higher in the group given steroids and/or cytotoxic agents than
in the group given no treatment (55% versus 25%; P < 0.05)
[49]. Approximately 50% of untreated patients versus 26% of
treated patients were in chronic renal failure at the end of
followup [49]. Analysis of some of the larger retrospective
studies suggests that remission of proteinuria is more likely to
occur in patients given steroids plus cytotoxic agents than in
those given only supportive therapy, and that rates of remission
are slightly higher for patients given steroids without cytotoxic
agents than for those given only supportive therapy (Table 3).
Controlled studies. Several controlled studies have compared
Sex Age Therapy
M 29 II
M
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17 I—Ill
M 42 Il—Ill A-Cy
IIF 63
M 45
A
AII
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III44
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M
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—
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Table 3. Remission of proteinuria in patients with idiopathic
membranous glomerulonephropathy and the nephrotic syndrome
according to various treatmentsa
Treatment No. of patients No. of remissionsb
No specific therapy 305 67 (21.9%)
Steroids 208 66 (31.7%)
Steroids and cytotoxic drugs 80 39 (48.7%)
The data are taken from retrospective studies [21, 22, 24, 31, 33, 39,
40, 48, 49, 51].
b Proteinuria, less than I g/day.
the effects of various treatments (Table 4). In a study by the
British Medical Research Council [52], 19 patients were ran-
domly allocated to a no-treatment group or to a group receiving
prednisone, at a mean dose of 32 mg/day for 3 weeks, followed
by 20 mg daily for at least 6 months. Treated patients had a
higher rate of remission and lower levels of serum creatinine
than did controls; moreover, none of the treated patients died or
developed uremia. These differences, however, were not statis-
tically significant, possibly because of the small number of
patients enrolled in the study. Donadio and colleagues reported
on 11 MGN patients treated with cyclophosphamide for one
year and an equal number of patients given no treatment; no
differences were found after 4 years of followup [53]. Lagrue
and coworkers randomly allocated 41 patients with MGN into
groups receiving chlorambucil, azathioprine, or placebo for one
year [54]. After 2 years of followup, 9 patients given chiorambu-
cil, 2 given placebo, and none given azathioprine had complete
remissions.
In a multicenter prospective study in the United States,
patients with idiopathic MGN and nephrotic syndrome were
allocated to placebo or to prednisone treatment; the predni-
sone-treated group received a mean dose of 125 mg every other
day [26]. If no response was seen after 2 months, the dose was
tapered off over 4 weeks. If remission of proteinuria occurred,
the dose was reduced more slowly. Of 34 treated patients, 8 had
complete and 14 had partial remissions of proteinuria; of 38
controls, 5 had complete and 6 had partial remissions. Several
patients, however, experienced relapses of proteinuria; hence,
at the end of the followup, the number of remissions between
the two groups did not differ significantly. Creatinine clearance
decreased more slowly in treated than in untreated patients
(—2% versus — 10% per year). Two patients in the treated group
and 11 patients in the control group manifested a doubling of
plasma creatinine, which represented the "stop point" of the
study. Following completion of the study and by the time of the
final report, 9 patients in the control group developed advanced
or end-stage renal failure, whereas only one in the treated group
did so [26]. No side effects were encountered in the treated
patients.
In an Australian multicenter trial, 27 patients with MGN were
given cyclophosphamide, dipyridamole, and warfann; 27 pa-
tients were not treated [55]. After 36 months, the treated
patients had less proteinuria and higher levels of serum albumin
than did the controls, but the levels of serum creatinine in the
two groups did not differ significantly. In a multicenter Canadi-
an trial, 39 patients were given alternate-day prednisone (45
mg/m2 for 6 months) and 47 were given supportive treatment
only [56]. No difference in the degree of proteinuria was
observed between the groups, but renal function was better
preserved in those receiving prednisone who had histologic
stage 1 or 2 disease.
In summary, although it is diflicult to draw any firm conclu-
sions from these studies, we have the impression that protract-
ed courses of high-dose prednisone or alkylating agents and—
perhaps even more convincingly—a combination of these drugs
can preserve renal function and favor remission of proteinuria,
at least in some patients.
An Italian multicenter study. Some years ago we discussed
with several of our Italian colleagues the feasibility of a
therapeutic trial using steroids and alkylating agents in alternat-
ing monthly cycles rather than simultaneously. The rationale
for such an approach was that alternating two drugs that
interfere with the immune response in different ways, and that
have different side effects, might enhance the therapeutic
benefit while reducing iatrogenic morbidity. After demonstrat-
ing in a pilot study that 6 months of alternating prednisolone and
chiorambucil therapy was well tolerated, we initiated a multi-
center, randomized, prospective trial in patients with idiopathic
MGN.* The early results of this study have been published [57],
but additional patients have now been enrolled and a longer
followup is available; consequently, I would like to provide an
update.
Let me first review the therapeutic schedule: 1 g of methyl-
prednisolone (MP) was given intravenously over 20 to 30
minutes for each of 3 consecutive days. Thereafter, MP (0.4 mg/
kg/day) or prednisone (0.5 mg/kg/day) was given orally in a
single dose, between 7 and 9 AM, for 27 days (cycle A). At the
end of this cycle, the steroid was discontinued and chlorambu-
cil, 0.2 mg/kg/day, was given for one month (cycle B); the dose
was lowered if the leukocyte count fell below 5000/mm3.
Alternating monthly cycles of MP and chlorambucil were given
for a total of 6 months.
Why was this schedule chosen? The half-life of MP given
intravenously in nephrotic patients is quite short, ranging
between 2 and 4 hours, with a mean of 2.5 hours [58]. The
brevity of the half-life of MP appears to reduce the untoward
effects of the steroid. For example, intravenous MP does not
inhibit the phagocytic function of leukocytes. In experimental
animals, it causes fewer side effects than does intramuscular
MP even when an intravenous dose 10 times that given intra-
muscularly is used [59]. In treating other immune-mediated
glomerular diseases, we have found that the intravenous admin-
istration of MP in 3 consecutive daily doses followed by the oral
administration of prednisone, 0.5 mg/kg, is efficacious and
accompanied by relatively fewer side effects than is the admin-
istration of "high-dose" oral steroids [60, 61]. Moreover, in a
controlled multicenter trial, we found that patients with ne-
phrotic syndrome due to minimal change disease had fewer
steroid-related side effects when treated with this regimen than
when given oral prednisone in higher doses [62]. Controlled
studies in renal transplantation also showed that intravenous
boluses of MP are as effective as high oral doses of prednisone,
*The following Renal Units participated in the trial: Ospedale Malpi-
ghi Bologna (Prof. Zucchelli), Ospedale Civile Lecco (Dr. Locatelli),
Ospedale Melegnano (Dr. Grassi), Ospedale Monza (Dr. Redaelli),
Ospedale Magenta (Prof. Novi), Ospedale Arezzo (Dr. Sasdelli), Ospe-
dale Vigevano (Dr. Volpini), Ospedale Alessandria (Dr. Taffun) Ospe-
dale Novara (Dr. Maduli), Ospedale Treviso (Prof. Dalla Rosa), and
Ospedale Maggiore Milano (Prof. Ponticelli).
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Table 4. Results of controlled, prospective studies in patients with idiopathic membranous nephropathy and the nephrotic syndrome
Author [Ref]
No. of
patients Therapy Results
Predniso(lo)ne
Black [52] 19 32 mg/day tapered to 20 mg/day for 6
months
No significant difference between treated
and untreated patients
American Collaborative Study [26] 70 100—150 mg on alternate days for 2
months, then gradually tapered
More rapid deterioration of renal
function in untreated patients
Cattran [56] 86 45 mg/m2 on alternate days for 6 months Preserved renal function in treated
patients with histologic stage 1 or 2
Cytotoxic agents
Donadio [53] 22 Cyclophosphamide 1.5—2.5 mg/kg/day
for 12 months
No significant difference between treated
and placebo group
Lagrue [54] 41 Chlorambucil, 0.2 mg/kg/day for 6
months, then 0.1 mg/kg/day for 6
months; azathioprine, 3 mg/kg/day for
6 months, then 2 mg/kg/day for 6
months
More remission of proteinuria in
chlorambucil (9) than in azathioprine
(0) or placebo (2) group
Tiller [55] 54 Cyclophosphamide, 1.5 mg/kg/day; and
warfarin and dipyridamole, 400 mg
daily, for 36 months
Significantly less proteinuria and higher
serum albumin levels in the treated
group
Table 5. Characteristics of patients at time of admission to Italian
Collaborative Study
Treated group Control group
Number of patients 38 35
Mean age (years) 42.5 11.5 42.9 16.7
Sex (M:F) 32:6 26:9
Mean duration of disease before
admission (months) 9.31 11.3 8.42 10,8
Mean plasma ereatininc (mgldl) 1.07 0.24 1.06 0.31
Number of hypertensive patients 5 7
Stage of glomerular lesions at
renal biopsy
I 10 7
II 19 19
III 7 7
IV 2 2
but that the latter regimen is associated with more morbidity
[63]. Finally, we found that oral prednisone given daily in a
single morning dose to recipients of a cadaveric renal transplant
is as well tolerated as are the same cumulative doses of steroid
given every other day [64]. On the basis of these observations,
we believe that a short course of intravenous MP followed by
moderate amounts of oral prednisone given in a single morning
dose is probably the best way to improve the therapeutic index
whenever vigorous corticosteroid therapy is needed.
We prefer chlorambucil to cyclophosphamide as the alkylat-
ing agent. Chiorambucil is generally well tolerated when given
for a short time; its myelosuppressive action is mild and rapidly
reversible. Alopecia and chemical cystitis are much less com-
mon with chlorambucil than with cyclophosphamide. Similarly,
fibrosis of the bladder occurs only rarely with chlorambucil.
Sterility is a complication of chlorambucil in both sexes. Males
appear to be more susceptible than are females; toxicity is
related both to the dose and to the duration of treatment.
Azoospermia can occur in prepubertal and pubertal males who
are given chiorambucil alone in cumulative doses exceeding 7
mg/kg 165], or in cumulative doses exceeding 17 mg/kg when the
drug is given with steroids [66]. To avoid this side effect, we
excluded children and adolescents from the trial.
Of greatest concern in using chlorambucil in adults is the
possibility that acute leukemia or malignant lymphoma will
develop. Patients without primary neoplasia in whom leukemia
has been reported after treatment with chlorambucil had been
given a mean dose of 7 g 167], and had received the drug for a
mean of 42 months [68]; patients with lymphoma subsequent to
chlorambucil therapy had been given a mean dose of 8 g for a
mean of 7.7 years [69]. These doses are considerably greater,
and the duration of treatment considerably longer, than those
used in our trial. It is comforting to note that no case of
leukemia has been reported in patients treated for less than 6
months or with less than I g of chlorambucil [70].
Adult patients with nephrotic syndrome and a histopathologic
diagnosis of MON on renal biopsy were admitted to our study.
Attempts were made to exclude patients with SLE, diabetes,
drug reaction, neoplasia, hepatitis, or other infectious diseases.
Patients with plasma creatinine levels higher than 1.7 mg/dl and
those who had had previous steroid or cytotoxic therapy also
were excluded. After obtaining informed consent, we randomly
assigned patients to the treatment or to the control group. The
patients were examined clinically every month and whenever
they reported symptoms. All patients have been followed for at
least one year since entry. The following definitions were used
to evaluate the outcomes: Complete remission was defined as a
reduction of proteinuria to 0.2 glday or less. Partial remission
was defined as urinary protein excretion between 0.21 to 2.0 g/
day and a normal plasma creatinine level. If protein excretion
remained greater than 2.0 g/day and plasma creatinine remained
stable, the patient's condition was regarded as being un-
changed, and if plasma creatinine increased by at least 50%
over baseline values, the patient was regarded as having
worsened.
Of the 81 adult patients with idiopathic membranous
nephropathy and nephrotic syndrome admitted to the study and
followed for at least one year, 38 were randomly allocated to
supportive treatment only, and 43 to the therapeutic regimen.
Data from the following 3 control patients were excluded from
Prognosis and treatment of membranous nephropathy 933ii]itI
62 cc' 3 III
34 9 6 III
•• 9 12 II
27 o' 52 II
32 a' 2 I
46 a' 10 II
64 9 1 II
16 0' 1 III
74 9 5 J!.
43 0' 2 III
59 a' 6 III
40 a' 14 I
35 cc' 2 I
70 9 12 I
33 9 2 I
16 9 36 I
40 a' 5 I
44 a' 10 II
•:::J
62 9 7 II
49 a' 20 IV
18 a' 2 II
41 a' 1
31 a' 2 II ...................................
60 a' 26 II
31 a' 9 IV
21. J
43 a' 1 II
42 a' :i-i- Ii,L JL
68 a' 12 II
.Th. a' 5 iii
I Worsened
Dialysis (10 pts)
Years 1 2 3 4 5 6 7 8 9
Fig. 4. Outcome in 35 patients with idiopathic membranous glomerulonephropathy and nephrotic syndrome randomly assigned to the control
group. The third column indicates the duration of the disease before randomization (months); the fourth column reftrs to the stage of the disease at
renal biopsy.
analysis: one woman had progressive renal insufficiency, devel-
oped hepatitis, and 2 years later died from liver and kidney
failure; one young woman developed a high titer of anti-dsDNA
antibodies one year after admission to the study; and a third
woman did not come in for followup after a few months. Data
from the following 5 patients in the experimental group were
excluded from analysis: one patient was found to have in-
creased blood glucose levels a few days after starting therapy;
one patient had gastric intolerance to chlorambucil; and 3
patients developed severe side effects (2 had peptic ulcer and
one had bronchopneumonitis). These complications of therapy
subsided completely but, because therapy had to be interrupted
within 1 to 3 months after its initiation, we did not include these
patients when assessing the possible benefits of treatment.
Therefore, 73 patients were included for the final analysis of the
results. There were no differences between the treated and
untreated groups in age, sex, previous duration of nephrotic
syndrome, plasma creatinine levels, hypertension, or histologic
stage at renal biopsy (Table 5).
The status of the control group is illustrated in Figure 4.
Among the 35 untreated patients, 4 achieved complete remis-
sion of proteinuria 3 to 4 years after entry into the study; this
interval is similar to that observed in the USA Collaborative
Study of the Adult Idiopathic Nephrotic Syndrome [26]. Pro-
teinuria reappeared, however, in 2 of these patients. Eight other
untreated patients showed partial remission of the nephrotic
syndrome. At present, after a mean followup of 44.7 24.5
months, 2 patients in the control group are free of proteinuria, 8
have non-nephrotic range proteinuria, 22 are still nephrotic, and
2 are being treated with dialysis. One patient, who showed
persistent nephrotic syndrome and progressive renal functional
impairment, died from a myocardial infarction after 2 years.
Among the 38 patients who completed the therapeutic
course, 23 (60%) achieved complete remission of proteinuria; in
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Fig. 5. Outcome in 38 patients with idiopathic membranous glomerulonephropathy and nephrotic syndrome randomly assigned to receive
chlorambucil or methyiprednisolone every other month for 6 months. (Symbols as in Fig. 4.)
most, proteinuria disappeared within the first year, but in 5
complete remission was not achieved until many months after
treatment was stopped. At present, 15 of these 23 patients
remain free of proteinuria 2 to 8 years after completing therapy;
the remaining 8 have had relapses. Eight additional patients
achieved partial remission of proteinuria, but in 2 the nephrotic
syndrome recurred. Therapy had no apparent effect on the
proteinuria in the remaining 7 patients, all of whom are still
nephrotic.
To summarize the outcome thus far in the treated group, after
a mean followup of 41.3 19.8 months, 15 patients are in
complete remission, 11 patients are in partial remission, and 11
patients still have nephrotic syndrome (Fig. 5); one patient, who
had not responded to therapy, died a few months later from lung
cancer. It is difficult, even retrospectively, to know whether
this patient had idiopathic MGN or whether the renal disease
should be considered as the first expression of the cancer. I am
inclined toward the latter view because we know that lung
cancer can be preceded by MGN, but I cannot exclude the
possibility that cytotoxic therapy played a role in the develop-
ment of his neoplasia, even though chlorambucil is much more
commonly associated with leukemia and lymphoma than with
carcinoma.
In addition to the 5 patients excluded from analysis, as I
noted earlier, several other patients experienced side effects
from therapy. Two patients had to have the dose of chiorambu-
cil reduced because of transient leukopenia, and 2 patients had
gastric pain during administration of the alkylating agent. The
steroid cycle produced tremor (2 patients), anxiety (1 patient),
and cramps (2 patients). One patient became obese and devel-
oped a cushingoid appearance. In another patient, the SGOT
rose to 78 IU (normal, 35 IU) and the SGPT increased to 196 IU
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Table 6. Clinical status at the end of followup in the Italian
Collaborative Study
Treated group Control group
Response 26 (68.5%) 10 (28.6%)
Complete remission 15 (39.5%) 2 (5.7%)
Partial remission 11(29.0%) 8 (22.9%)
No response 12 (31.5%) 25 (71.4%)
Unchanged 12 (31.5%) 15 (42.9%)
Worsened 0 10 (28.5%)
(normal, 40 IU) by the end of the therapeutic course, but these
values had returned to normal 4 weeks after the therapy was
completed.
Fifteen of the 29 patients in the treated group with stage 1 or 2
glomerular lesions on renal biopsy experienced complete remis-
sions, whereas none of the 9 with stage 3 or 4 did so (P < 0.05).
Moreover, 13 of 25 patients with a duration of the disease
shorter than 8 months became free of proteinuria, whereas only
2 of the 13 with longer duration of MGN did so (P < 0.01). The
importance of prompt treatment has been noted in other studies
[42]. We could detect no influence of age, sex, or HLA status
on the response of proteinuria to therapy.
In summary, 26 of 38 patients who received therapy (68%)
versus 10 of 35 who were given only supportive treatment (28%)
have thus far sustained complete or partial remissions of the
nephrotic syndrome (P < 0.05, Table 6).
No patient in the treated group had any appreciable increase
in plasma creatinine, whereas 10 of 35 untreated patients
manifested an increase of at least 50% over their respective
baseline values; 2 of these patients are now receiving
chronic dialysis treatment. Patients who worsened did not differ
in age, sex, or stage of disease from those who did not.
Restricting consideration only to those followed for at least 4
years, one finds a marked difference in plasma creatinine
between treated and untreated patients; the mean values are
virtually unchanged after 4 years in the experimental group but
are approximately doubled in the control group (Fig. 6). There-
fore, with the therapeutic schedule we used, approximately
60% of patients achieved complete remission of proteinuria,
and two-thirds of these have remained in remission over the
subsequent years. Women, patients with short duration of
MGN, and those with mild glomerular changes on renal biopsy
were the most likely to achieve and maintain complete
remission of proteinuria. Our observations also suggest that this
therapy can halt, or at least dramatically slow, the progression
to renal insufficiency.
Conclusions
Idiopathic MGN is often considered an indolent disease. Yet
approximately one-half of the patients with this condition die or
develop renal failure within 10 to 15 years of the onset of
symptoms. Moreover, protracted nephrotic syndrome can lead
to protein malnutrition, hyperlipidemia, increased susceptibility
to infection [71], hypercoagulability with thromboembolic com-
plications [72], and osteodystrophy [73]. Spontaneous remis-
sion of the nephrotic syndrome does occur, particularly in
children, in women, and in patients with mild glomerular and
interstitial lesions on renal biopsy. When it does occur, howev-
er, spontaneous remission is not generally manifest until the
patient has had the nephrotic syndrome for several years.
Consequently, patients whose proteinuria eventually subsides
without therapy are often at risk over a long interval for
complications of the nephrotic syndrome.
Several uncontrolled and controlled trials have reported
favorable results with corticosteroids and/or cytotoxic agents.
One of the most convincing series was the American Collabora-
tive Study [26]; this study demonstrated that short-term treat-
ment with alternate-day, high-dose prednisone improved pro-
teinuria and slowed the progression to renal failure. Because
early relapses of proteinuria frequently occurred, however, the
possibility arose that the duration of therapy might have been
too short to produce sustained remission. Longer and more
vigorous therapy with steroids alone might have been more
effective, but it also might have been more toxic.
In an effort to obtain better therapeutic results while minimiz-
ing the risk of side effects, we gave chlorambudil and methyl-
prednisolone, each for one month at a time, in an alternating
schedule for a total of 6 months. No treated patient has
developed renal insufficiency during a maximum followup peri-
od of 8 years. A sustained remission of the nephrotic syndrome
has been observed in 68% of patients. Because remission was
generally achieved after several months of therapy, we sur-
mise that therapy for shorter intervals might have been less
successful. As with most aggressive therapies, the regimen
employed was not devoid of side effects. We would estimate
from our experience that some patients will not tolerate this
treatment protocol, and approximately 8% to 10% will likely
have severe side effects.
We believe that idiopathic MGN is a treatable disease.
Unfortunately, the therapy is potentially toxic and the clinician
must decide, as always, whether the benefits are worth the
risks. Accurate clinical evaluation before therapy starts and
careful clinical and laboratory monitoring during therapy are
required to reduce the risks related to treatment. The likelihood
of achieving complete remission of symptoms in MGN appears
to be increased the earlier in the course of the illness treatment
is started.
Questions and answers
DR. SERAFINO GARELLA: Do you include histologic grading
among the factors you now use to identify patients for treat-
ment? You indicated that patients with stage 3 and 4 membra-
nous lesions responded poorly, if at all, to therapy. Do you
recommend treating only patients with stage 1 and 2 lesions?
DR. P0NTIcELLI: Even though therapy is unlikely to induce
remission of proteinuria in patients with stage 3 or 4 lesions, we
recommend treatment in the hope that progression to renal
insufficiency will be slowed. None of the 9 patients who had
lesions at stage 3 or 4 and who completed our therapeutic
protocol manifested a rise in plasma creatinine, whereas control
patients with stage 3 or 4 lesions did not fare nearly as well.
DR. DIEGO BRANcAcclo (Chief of Nephrology, S. Paolo
Hospital, Milano): Cyclophosphamide is well accepted among
nephrologists and is often included as a therapeutic agent in
patients with primary glomerular diseases. Could you go into
more detail as to why you selected chlorambucil rather than
cyclophosphamide?
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DR. PONTICELLI: As I mentioned, we chose chiorambucil
mainly because it produces fewer instances of chemical cystitis
than does cyclophosphamide and hence does not result in
bladder fibrosis. Alopecia is also less frequent. It is difficult to
say whether one of these two drugs is more active than the
other in MON. Lagrue administered chlorambucil for one year
to 16 patients and achieved complete remission of proteinuria in
9 [541. Donadio used cyclophosphamide for one year in 11
patients with MGN, none of whom became free of proteinuria
[53]. These studies suggest that chlorambucil might be more
effective than cyclophosphamide in the treatment of MON. On
Unchanged the other hand, I am aware that some other groups in Italy used
a protocol similar to the one we proposed but substituted
cyclophosphamide for chlorambucil. The results obtained in
MGN were similar to those achieved with our multicenter trial.
Moreover, a German cooperative study compared the effects of
chlorambucil (0.15 mg/kg for 8 weeks) to those of cyclophos-
phamide (2 mg/kg for 8 weeks) in children with frequently
gg relapsingor steroid-dependent nephrotic syndrome [74]; neither
• the effectiveness of therapy nor the acute complication rate
differed between the two groups. Thus, at present, there is no
evidence that one drug is superior to the other for the treatment
of MON.
DR. JORDAN J. COHEN: One of the major concerns with the
use of chlorambucil is infertility. Did you have occasion to
perform sperm counts or monitor menstrual cycles in the
patients who received chiorambucil in your study?
DR. PONTICELL!: No, we did not study this particular aspect.
However, the infertility caused by alkylating agents is most
frequent when these drugs are used in prepubertal and pubertal
patients. Moreover, corticosteroids appear to protect the go-
nads from chlorambucil-induced toxicity [66]. Our patients
were adults and were given a cumulative chlorambucil dose of
18 mg/kg, administered every other month alternately with
methyiprednisolone. Thus the risk of gonadal dysfunction in
these patients theoretically should be minimal. No specific data
are available supporting this assumption, however.
DR. GIULTANO COLA5ANTI (Division of Nephrology, S.
Carlo Hospital, Milano): In your opinion, what aspects of the
pathogenesis of MON are most likely to be influenced by the
immunosuppressive regimen you employed?
DR. PONTICELLt: That is a difficult question. The two drugs
we used are known to interfere with different steps in the
immune response, and therefore with immune-complex forma-
tion and deposition in the glomeruli.
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DR. TuLLI0 BERTANI (Division of Nephrology, Ospedale
Bergamo): It would be of great interest to correlate the clinical
outcomes in your untreated and treated patients with changes in
the histopathologic appearance of the kidneys. Do you have
systematic observations on repeated renal biopsies in the
untreated and treated groups?
DR. P0NTIcELLI: Professor Zucchelli can give us some
information about that.
PROF. PIETR0 ZUCCHELLI (Chief, Division of Nephrology,
Malpighi Hospital, Bologna): Up to now it has not been clearly
shown whether remission of proteinuria and stability of renal
function are associated with histologic recovery in patients with
MGN. To determine the correlation between clinical course and
morphologic changes, we repeated the renal biopsies in 25 of
the patients who completed the trial. Membranous nephropathy
was classified histologically according to the scheme proposed
by Ehrenreich and Churg [21 and by Gartner et al [75]. Briefly, 5
evolutionary stages were identified in these studies, as follows:
stage 1, subepithelial deposits; stage 2, spike formation; stage 3,
incorporation of deposits; stage 4, disappearance of deposits;
stage 5, repair. Figure 7 summarizes our followup observations
in these patients. Six of the 9 patients with complete and stable
remission were classified as having repair of disease (stage 5) on
the second biopsy. All patients with stage 3 had had stage 1 or 2
lesions at the time of the original biopsy. No patient who
experienced only partial remission was classified as having
stage 5 at the time of the second biopsy, but many of these
patients showed the disappearance of deposits with numerous
electron-lucent vacuolated areas within the thickened mem-
brane (stage 4). Two patients had acute relapse with fresh and
small deposits superimposed on stage 4 lesions (stage 4).
Finally, patients whose clinical course remained unchanged
betweei the first and the second biopsy remained in the same
stage or progressed to stage 3 or 4.
DR. GIUSEPPE REMUZZI (Mario Negri Institute, Bergamo):
Did the prevalence of renal vein thrombosis differ among your
treated and untreated patients?
DR. PONTICELLI: We have not attempted to answer that
question. It is unknown whether renal vein thrombosis has a
clear effect on proteinuria or on renal function, with the
possible rare exception of patients who develop an acute
thrombosis of the main renal vein [36]. Therefore, because the
procedures for correctly diagnosing renal vein thrombosis are
expensive and not without side effects, we subjected patients to
these procedures only when we suspected acute renal vein
thrombosis because of a rapid deterioration of renal function
following an episode of flank pain.
DR. GIANFRANCO RizzoNI (Chief of Pediatric Nephrology,
University of Padova): You mentioned the factors that correlat-
ed with the disappearance of proteinuria in the treated group.
Did you investigate whether there are factors associated with
spontaneous remission of proteinuria in untreated patients? It
would be very useful for us to be able to identify in advance
patients who have a good prognosis.
DR. PONTICELLI: Only 2 patients in the control group had
complete remission of proteinuria at the end of followup.
Consequently, it is difficult to identify any factor that might
have fostered the remission. You might find it interesting,
however, that both the untreated patients who had a complete
remission had stage 1 glomerular lesions at renal biopsy.
DR. Ezio M0vILLI (Division of Nephrology, Brescia Hospi-
tal): You included only patients with normal renal function in
your therapeutic trial. What do you think about the advisability
of treating patients with MGN who have already developed
some degree of renal insufficiency?
DR. PONTICELL1: I have used the same therapeutic protocol
in only 2 patients with renal insufficiency. In both patients, a
decrease in the plasma creatinine concentration was observed
(from 2.6 to 1.5 mg!dl, and from 4.0 to 2.0 mg/dl, respectively).
Both these patients were over 65 years of age, and both
experienced severe, albeit reversible, complications. One de-
veloped severe leukopenia and sepsis during the sixth month of
therapy; the other developed pneumonia during the fifth month.
I think that our therapy might be effective in slowing the
progression of the disease in patients with moderate renal
insuffiency, but that the toxicity of therapy might be increased
in these patients, particularly if they are in the older age group.
DR. COHEN: In discussing the natural history of membranous
nepbjopathy, you referred to the prognostic importance of
interstitial changes. You also have emphasized that the stage of
the glomerular lesion is an important determinant of the natural
history of the disease. Do you think the degree of interstitial
change constitutes an independent risk factor, or do you believe
that a strong correlation exists between the glomerular lesions
and the interstitial lesions?
DR. PONTICELLI: We found a good correlation between the
severity of glomerular lesions and that of interstitial changes. I
therefore am inclined to think that in most cases the glomerular
and interstitial changes are part of the same process, the
obvious exception being patients with drug-related interstitial
nephritis.
DR. GARELLA: How extensive an evaluation do you recom-
mend to exclude an underlying malignancy as the cause of
MON in an adult?
DR. PONTICELLI: In most cases in which an underlying
cancer is responsible for MON, the clinician can make a correct
diagnosis without a sophisticated workup. Recall that the types
of neoplasia most frequently associated with MON are lung,
breast, kidney, and colorectal carcinomas. Lung cancer is
usually evident on routine chest x-ray. Breast cancer is usually
revealed by a careful physical examination. The presence of a
renal tumor is generally identified by an intravenous pyelogram
and/or a kidney ultrasonogram, one or both of which are part of
the routine evaluation of a nephrotic patient who is scheduled to
have a renal biopsy. A patient with MGN who is over the age of
40, and who complains of weight loss, anorexia, changes in
bowel habits, or changes in upper gastrointestinal function
should be evaluated with an x-ray of the stomach and of the
bowel and with repeated tests of the stool for occult bleeding.
Unless other clinical findings suggest a specific malignancy, I
do not think that the mere presence of MGN warrants a more
extensive evaluation.
DR. GARELLA: Nephrotic syndrome due to idiopathic MGN
has been attributed in the past to the deposition of circulating
immune complexes. More recently, the possibility has been
raised that so-called "planted" antigens, with local formation of
antigen-antibody complexes in the glomerular basement mem-
brane, might play a more significant role in producing immune
injury. Progression of the disease frequently has been attributed
to the persistence of proteinuria, to the concurrence of hyper-
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tension and, on occasion, to genetic factors. Do you think that
the response of this condition to your immunosuppressive
regimen can be used to shed some light on the pathogenetic
mechanisms of MON? Also, do you think cyclosporine might
be yet another agent that could interfere with the immune
mechanism responsible for this disease?
DR. P0NTICELLI: It is difficult to draw any suggestions about
this disease's pathogenesis from our trial, except to say that
therapy might interfere with the immune response, and there-
fore could be effective in preventing immune-complex forma-
tion, whether complex formation occurs in the circulation or in
situ. As far as the use of cyclosporine in MGN is concerned, I
am aware of a Canadian study presented by Cattran at a
workshop in Basel [761. Patients with various forms of primary
chronic glomerulonephritis, including MGN, and a decline of
renal function of at least 10% in the last year of followup were
given cyclosporine for 4 months. In the 28 patients admitted to
the study, the slope of the reciprocal of the plasma creatinine
became stable and flat during the treatment. After the drug was
discontinued, there was again a trend towards deterioration, but
it was less rapid than before cyclosporine. In 7 patients with
MGN, proteinuria decreased during treatment but increased
after withdrawal of cyclosporine.
DR. ZUCCHELLI: In Heymann nephritis, the deposition of
C5b-C9 complement components is associated with the devel-
opment of proteinuria. Do you have any data about the
deposition of complement components in the glomeruli in
relation to the clinical outcome of your patients?
DR. PONTICELLI: No, I do not.
DR. Rocco MI5IANI (Chief of Nephrology, Treviglio Hospi-
tal, Treviglio): You noted the prognostic importance of associ-
ated hypertension in patients with MGN. Was the incidence of
hypertension comparable in your treated and untreated groups?
Also, what role do vascular changes play in the progression of
membranous glomerulopathy? Do you think that the bad prog-
nosis in older patients might be related to the increased vascular
changes?
DR. P0NTIcELLI: The frequency of hypertension was similar
in our two groups. Obvious vascular changes were rare in our
patients, but they were more common in older patients, so your
hypothesis might be correct.
DR. COHEN: In your treated group, some patients had a
partial or complete remission early in the therapeutic course
and then relapsed. Is it your practice to re-treat such patients
with new cycles of your therapeutic regimen? If so, what
criteria do you use to select patients for re-treatment?
DR. P0NTIcELLI: Our main concern is to avoid as far as
possible the side effects of therapy. For this reason we did not
re-treat patients with early relapses of their nephrotic syn-
drome. I believe that patients should be treated again only if
several years have elapsed from the first therapeutic course, by
which time the effects of the previous treatment presumably
have waned.
DR. REMUZZI: Do you consider the steroid pulses given for 3
days every other month an essential part of treatment? In other
words, would you expect different results if the same schedule
of steroids were to be given without the first 3 days of
intravenous pulses?
DR. PONTICELLI: I believe that the 3 steroid pulses given
every other month play an important role. As I mentioned
before, steroid-pulse therapy followed by moderate oral predni-
sone doses can achieve at least the same results as does
prolonged, high-dose oral prednisone. I think that giving 0.5 mg/
kg/day of prednisone without steroid pulses might not be
sufficient therapy for MON. Let me remind you of the con-
trolled study by Black and coworkers [52]. Patients who
received moderate doses of oral prednisone did not show any
significant advantage when compared to untreated controls.
DR. REMuZZI: One gram of methylprednisolone is likely to
inhibit renal prostaglandins, whereas conventional doses proba-
bly do not. You are aware that in the last few years prostaglan-
dins have been considered possible mediators of glomerular
injury, particularly in respect to proteinuria. I wonder whether
methylprednisolone exerts a favorable influence on the evolu-
tion of the disease because it reduces proteinuria in the early
phase of treatment.
DR. PONTICELLI: I agree that this possibility should be
investigated. We have much to learn about the mechanisms of
action of intravenous methylprednisolone.
Reprint requests to Dr. C. Ponticelli, Divisione di Nefrologia e
Dialisi, Ospedale Maggiore Policlinico, via Commenda 15, 20122
Milano, Italy
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